



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 60254

Title: Review of 10 years of research on breast cancer patients: Focus on indoleamine 2, 3-dioxygenase

Reviewer's code: 05387238

Position: Editorial Board

Academic degree: PhD

Professional title: Associate Research Scientist

Reviewer's Country/Territory: Israel

Author's Country/Territory: Pakistan

Manuscript submission date: 2020-10-22

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2020-11-30 11:24

Reviewer performed review: 2020-11-30 12:35

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

To the authors: The manuscript intends to describe the role of indoleamine 2, 3-dioxygenase as a therapeutic target or a valuable prognostic marker in breast cancer. Although the topic is interesting, the manuscript fails to explain it clearly. The manuscript is a group of sentences citing different papers in a confused manner. 1. The manuscript must be subjected to an extended English revision. 2. The authors must present the content of the review separated according to different sub-themes under subtitles (e.g. IDO expression in breast cancer subtypes, IDO as a prognostic marker, etc.). Take examples of other reviews. 3. Clinical trials must be cited (e.g. phase II clinical trial IDO inhibitor (1-Methyl-Tryptophan;1-MT) is used to treat the metastatic breast cancer patients). 4. Revise the papers cited, the authors must be accurate to what is written in the original paper (e.g. The authors: "Lyon et al. observed high tryptophan degradation in early stage breast cancer along with neuropsychiatric symptoms[22] . Lyon et al. wrote: Given the multifactorial role of IDO and TRP, further research is necessary to determine the relationships among these important biological factors and neuropsychiatric symptoms, treatment efficacy, prognosis, and recurrence in women with BCA. 5. The authors must write the review in a fluently manner. Must connect between sentences of the same subject and pay attention to the contradictory function of IDO during the literature.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 60254

Title: Review of 10 years of research on breast cancer patients: Focus on indoleamine 2, 3-dioxygenase

Reviewer’s code: 02525366

Position: Editorial Board

Academic degree: MD

Professional title: Professor

Reviewer’s Country/Territory: United States

Author’s Country/Territory: Pakistan

Manuscript submission date: 2020-10-22

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2020-11-30 19:39

Reviewer performed review: 2020-11-30 19:50

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Interesting review of potentially timely subject. Need to polish up the English style.